KR20030045194A - 락탐 화합물 - Google Patents

락탐 화합물 Download PDF

Info

Publication number
KR20030045194A
KR20030045194A KR10-2003-7006660A KR20037006660A KR20030045194A KR 20030045194 A KR20030045194 A KR 20030045194A KR 20037006660 A KR20037006660 A KR 20037006660A KR 20030045194 A KR20030045194 A KR 20030045194A
Authority
KR
South Korea
Prior art keywords
formula
methyl
amino
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7006660A
Other languages
English (en)
Korean (ko)
Inventor
토마스 미첼 코에닝
제임스 에드문드 아우디아
데이비드 미첼
스테이시 레이 맥다니엘
린 앤 부실리
게리 로웰 엔겔
제임스 아브라함 에이킨스
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20030045194A publication Critical patent/KR20030045194A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
KR10-2003-7006660A 2000-11-17 2001-11-02 락탐 화합물 Ceased KR20030045194A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
US60/249,656 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
KR20030045194A true KR20030045194A (ko) 2003-06-09

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7006660A Ceased KR20030045194A (ko) 2000-11-17 2001-11-02 락탐 화합물

Country Status (33)

Country Link
US (1) US20040248878A1 (enExample)
EP (1) EP1353910B1 (enExample)
JP (1) JP4116431B2 (enExample)
KR (1) KR20030045194A (enExample)
CN (2) CN101624372A (enExample)
AR (1) AR031356A1 (enExample)
AT (1) ATE362919T1 (enExample)
AU (2) AU2002224321B2 (enExample)
BR (1) BR0115424A (enExample)
CA (1) CA2425497C (enExample)
CY (1) CY1106682T1 (enExample)
CZ (1) CZ20031340A3 (enExample)
DE (1) DE60128587T2 (enExample)
DK (1) DK1353910T3 (enExample)
DZ (1) DZ3454A1 (enExample)
EA (1) EA006919B1 (enExample)
EC (1) ECSP034598A (enExample)
ES (1) ES2286162T3 (enExample)
HR (1) HRP20030385A2 (enExample)
HU (1) HUP0301862A3 (enExample)
IL (1) IL155275A0 (enExample)
MX (1) MXPA03004250A (enExample)
MY (1) MY141607A (enExample)
NO (1) NO325217B1 (enExample)
PE (1) PE20020798A1 (enExample)
PL (1) PL211018B1 (enExample)
PT (1) PT1353910E (enExample)
SK (1) SK287794B6 (enExample)
SV (1) SV2003000741A (enExample)
TW (1) TWI235151B (enExample)
UA (1) UA77165C2 (enExample)
WO (1) WO2002040451A2 (enExample)
ZA (1) ZA200303411B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9054614B2 (en) 2012-01-06 2015-06-09 Samsung Electronics Co., Ltd. Apparatus and method to control BLDC motor

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2333008T3 (es) 2002-12-20 2010-02-16 Glaxo Group Limited Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos.
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
BRPI0610532A2 (pt) 2005-04-08 2010-06-29 Daiichi Sankyo Co Ltd derivado de piridilmetilsulfona
US8258302B2 (en) * 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
IL296723A (en) 2020-03-26 2022-11-01 Seagen Inc Methods of treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL158355A0 (en) * 1996-12-23 2004-05-12 Elan Pharm Inc CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2324474A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1230220A1 (en) * 1999-11-09 2002-08-14 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9054614B2 (en) 2012-01-06 2015-06-09 Samsung Electronics Co., Ltd. Apparatus and method to control BLDC motor

Also Published As

Publication number Publication date
MXPA03004250A (es) 2003-09-22
WO2002040451A3 (en) 2003-08-28
AR031356A1 (es) 2003-09-17
CN100516047C (zh) 2009-07-22
JP4116431B2 (ja) 2008-07-09
NO325217B1 (no) 2008-02-25
US20040248878A1 (en) 2004-12-09
ZA200303411B (en) 2004-08-02
CN1575282A (zh) 2005-02-02
NO20032215L (no) 2003-07-16
CN101624372A (zh) 2010-01-13
IL155275A0 (en) 2003-11-23
ES2286162T3 (es) 2007-12-01
CZ20031340A3 (cs) 2004-06-16
PT1353910E (pt) 2007-08-20
SV2003000741A (es) 2003-01-13
MY141607A (en) 2010-05-31
CA2425497C (en) 2010-08-17
ATE362919T1 (de) 2007-06-15
HRP20030385A2 (en) 2003-08-31
SK5432003A3 (en) 2004-09-08
WO2002040451A2 (en) 2002-05-23
CA2425497A1 (en) 2002-05-23
DK1353910T3 (da) 2007-09-10
AU2432102A (en) 2002-05-27
DE60128587T2 (de) 2008-01-31
ECSP034598A (es) 2003-06-25
EA200300579A1 (ru) 2003-12-25
BR0115424A (pt) 2003-10-21
PL211018B1 (pl) 2012-03-30
EP1353910B1 (en) 2007-05-23
UA77165C2 (en) 2006-11-15
PE20020798A1 (es) 2002-09-06
PL360991A1 (en) 2004-09-20
NO20032215D0 (no) 2003-05-15
DZ3454A1 (fr) 2002-05-23
SK287794B6 (sk) 2011-10-04
EP1353910A2 (en) 2003-10-22
HUP0301862A3 (en) 2007-09-28
EA006919B1 (ru) 2006-04-28
AU2002224321B2 (en) 2006-10-19
DE60128587D1 (de) 2007-07-05
CY1106682T1 (el) 2012-05-23
TWI235151B (en) 2005-07-01
JP2004521084A (ja) 2004-07-15
HUP0301862A2 (hu) 2003-09-29

Similar Documents

Publication Publication Date Title
KR100819679B1 (ko) 베타-아밀로이드 펩티드 방출 또는 합성을 억제하는 락탐화합물
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
KR20030045194A (ko) 락탐 화합물
AU2002224321A1 (en) Lactam compound
JP2004521084A5 (enExample)
US7468365B2 (en) Lactam compound
EP1345955B1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
US20040077627A1 (en) Lactam compound
NZ525365A (en) Lactam compound
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070921

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20071226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20070921

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I